TY - JOUR
T1 - The role of microbiome in pancreatic cancer
AU - Li, Jenny Jing
AU - Zhu, Mojun
AU - Kashyap, Purna C.
AU - Chia, Nicholas
AU - Tran, Nguyen H.
AU - McWilliams, Robert R.
AU - Bekaii-Saab, Tanios S.
AU - Ma, Wen Wee
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/9
Y1 - 2021/9
N2 - Recent studies of the human microbiome have offered new insights into how the microbiome can impact cancer development and treatment. Specifically, in pancreatic ductal adenocarcinoma (PDAC), the microbiota has been shown to modulate PDAC risk, contribute to tumorigenesis, impact the tumor microenvironment, and alter treatment response. These findings provide rationale for further investigations into leveraging the microbiome to develop new strategies to diagnose and treat PDAC patients. There is growing evidence that microbiome analyses have the potential to become easily performed, non-invasive diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. More excitingly, there is now emerging interest in developing interventions based on the modulation of microbiota. Fecal microbiota transplantation, probiotics, dietary changes, and antibiotics are all potential strategies to augment the efficacy of current therapeutics and reduce toxicities. While there are still challenges to overcome, this is a rapidly growing field that holds promise for translation into clinical practice and provides a new approach to improving patient outcomes.
AB - Recent studies of the human microbiome have offered new insights into how the microbiome can impact cancer development and treatment. Specifically, in pancreatic ductal adenocarcinoma (PDAC), the microbiota has been shown to modulate PDAC risk, contribute to tumorigenesis, impact the tumor microenvironment, and alter treatment response. These findings provide rationale for further investigations into leveraging the microbiome to develop new strategies to diagnose and treat PDAC patients. There is growing evidence that microbiome analyses have the potential to become easily performed, non-invasive diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. More excitingly, there is now emerging interest in developing interventions based on the modulation of microbiota. Fecal microbiota transplantation, probiotics, dietary changes, and antibiotics are all potential strategies to augment the efficacy of current therapeutics and reduce toxicities. While there are still challenges to overcome, this is a rapidly growing field that holds promise for translation into clinical practice and provides a new approach to improving patient outcomes.
KW - Biomarker
KW - Microbiome
KW - Microbiota modulation
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85113772596&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113772596&partnerID=8YFLogxK
U2 - 10.1007/s10555-021-09982-2
DO - 10.1007/s10555-021-09982-2
M3 - Review article
C2 - 34455517
AN - SCOPUS:85113772596
SN - 0167-7659
VL - 40
SP - 777
EP - 789
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
IS - 3
ER -